The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin

Histopathology

Volumn 49, Issue 2, 2006, Pages 138-151

  Durnez, A ^a   Verslype, C ^a   Nevens, F ^a   Fevery, J ^a   Aerts, R ^a   Pirenne, J ^a   Lesaffre, E ^a   Libbrecht, L ^a   Desmet, V ^a   Roskams, T ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

fetoprotein; catenin; Carcinoma; CK7 and CK19: hepatocellular carcinoma; Progenitor cell

Indexed keywords

ALPHA FETOPROTEIN; ANTIGEN; BETA CATENIN; BILIRUBIN; CANALICULAR POLYCLONAL CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; CYTOKERATIN 7; HEPATITIS B CORE ANTIBODY; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER RECURRENCE; FIBROSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PARENCHYMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STEM CELL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; KERATINS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; STEM CELLS;

EID: 33645551138     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02468.x     Document Type: Article

References (59)

1. Forns X, Sanchez Tapias JM, Pares A et al. Expected developments in hepatology. Best Pract. Res. Clin. Gastroenterol. 2002; 16; 957-970.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001; 94; 153-156.
3. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31; 11-24.
4. Osborn M, van Lessen G, Weber K, Kloppel G, Altmannsberger M. Differential diagnosis of gastrointestinal carcinomas by using monoclonal antibodies specific for individual keratin polypeptides. Lab. Invest. 1986; 55; 497-504.
5. Van Eyken PL, Sciot R, Van Damme B, De Wolf-Peeters C, Desmet VJ. Keratin immunohistochemistry in normal human liver. Cytokeratin pattern of hepatocytes, bile ducts and acinar gradient. Virchows Arch. A. Pathol. Anat. Histopathol. 1987; 412; 63-72.
6. Lai YS, Thung SN, Gerber MA, Chen ML, Schaffner F. Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas. Arch. Pathol. Lab. Med. 1989; 113; 134-138.
7. Roskams T, De Vos R, van Eyken P et al. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J. Hepatol. 1998; 29; 455-463.
8. Van Eyken PL, Sciot R, Paterson A et al. Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum. Pathol. 1988; 19; 562-568.
9. Wu PC, Fang JW, Lau VK et al. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am. J. Pathol. 1996; 149; 1167-1175.
10. Robrechts C, De Vos R, Van den Heuvel M et al. Primary liver tumour of intermediate (hepatocyte-bile duct cell) phenotype: a progenitor cell tumour? Liver 1998; 18; 288-293.
11. Yoon DS, Jeong J, Park YN et al. Expression of biliary antigen and its clinical significance in hepatocellular carcinoma. Yonsei Med. J. 1999; 40; 472-477.
12. Uenishi T, Kubo S, Yamamoto T et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003; 94; 851-857.
13. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am. J. Pathol. 1989; 134; 1347-1363.
14. Sell S. Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology 2001; 33; 738-750.
15. Santoni-Rugiu E, Nagy P, Jensen MR, Factor VM, Thorgeirsson SS. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. Am. J. Pathol. 1996; 149; 407-428.
16. Hixson DC, Brown J, Mcbride AC, Affigne S. Differentiation status of rat ductal cells and ethionine-induced hepatic carcinomas defined with surface-reactive monoclonal antibodies. Exp. Mol. Pathol. 2000; 68; 152-169.
17. Ishak KG, Anthony PP, Sobin LH. Histological typing of tumors of the liver. Geneva: World Health Organisation 1994.
18. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am. J. Pathol. 1993; 143; 1050-1054.
19. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum. Pathol. 2002; 33; 1175-1181.
20. Ruffin MT. Fibrolamellar hepatoma. Am. J. Gastroenterol. 1990; 85; 577-581.
21. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7; 462-503.
22. International Union Against Cancer. Liver. In Sobin LH and Wittekind CH eds. TNM classification of malignant tumors. New York: Wiley-Liss 1997; 74-77.
23. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20; 15-20.
24. Libbrecht L, De Vos R, Cassiman D et al. Hepatic progenitor cells in hepatocellular adenomas. Am. J. Surg. Pathol. 2001; 25; 1388-1396.
25. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996; 334; 693-699.
26. Roskams TA, Theise ND, Balabaud C et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004; 39; 1739-1745.
27. Theise ND, Saxena R, Portmann BC et al. The canals of Hering and hepatic stem cells in humans. Hepatology 1999; 30; 1425-1433.
28. Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin. Liver Dis. 2003; 23; 385-396.
29. Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am. J. Pathol. 1949; 25; 647-655.
30. Van Eyken PL, Sciot R., Brock P et al. Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver. Histopathology 1990; 17; 101-107.
31. Hsia CC, Evarts RP, Nakatsukasa H, Marsden ER, Thorgeirsson SS. Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology 1992; 16; 1327-1333.
32. Bisgaard HC, Parmelee DC, Dunsford HA, Sechi S, Thorgeirsson SS. Keratin 14 protein in cultured nonparenchymal rat hepatic epithelial cells: characterization of keratin 14 and keratin 19 as antigens for the commonly used mouse monoclonal antibody OV-6. Mol. Carcinogen. 1993; 7; 60-66.
33. De Vos R, Desmet V. Ultrastructural characteristics of novel epithelial cell types identified in human pathologic liver specimens with chronic ductular reaction. Am. J. Pathol. 1992; 140; 1441-1450.
34. Sell S. Cellular origin of cancer: dedifferentiation or stem cell maturation arrest? Environ. Health Perspect. 1993; 101 (Suppl. 5); 15-26.
35. Braun L, Mikumo R, Fausto N. Production of hepatocellular carcinoma by oval cells: cell cycle expression of c-myc and p53 at different stages of oval cell transformation. Cancer Res. 1989; 49; 1554-1561.
36. Goyette M, Faris R, Braun L, Hixson D, Fausto N. Expression of hepatocyte and oval cell antigens in hepatocellular carcinomas produced by oncogene-transfected liver epithelial cells. Cancer Res. 1990; 50; 4809-4817.
37. Steinberg P, Steinbrecher R, Radaeva S et al. Oval cell lines OC/CDE 6 and OC/CDE 22 give rise to cholangio-cellular and undifferentiated carcinomas after transformation. Lab. Invest. 1994; 71; 700-709.
38. Libbrecht L, Desmet V, Van Damme B, Roskams T. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J. Hepatol. 2000; 33; 76-84.
39. Roskams T. Progenitor cell involvement in cirrhotic human liver diseases: from controversy to consensus. J. Hepatol. 2003; 39; 431-434.
40. Theise ND, Yao JL, Harada K et al. Hepatic 'stem cell' malignancies in adults: four cases. Histopathology 2003; 43; 263-271.
41. Kim H, Park C, Han KH et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J. Hepatol. 2004; 40; 298-304.
42. Roskams T. The role of immunohistochemistry in diagnosis. Clin. Liver Dis. 2002; 6; 571-89, x.
43. Xiao JC, Ruck P, Adam A, Wang TX, Kaiserling E. Small epithelial cells in human liver cirrhosis exhibit features of hepatic stem-like cells: immunohistochemical, electron microscopic and immunoelectron microscopic findings. Histopathology 2003; 42; 141-149.
44. Roskams T, Yang SQ, Koteish A et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am. J. Pathol. 2003; 163; 1301-1311.
45. Ding SJ, Li Y, Tan YX et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol. Cell Proteomics 2004; 3; 73-81.
46. Dobashi N, Fujita J, Murota M et al. Binding of recombinant human cytokeratin 19 to laminin: a possible role in interaction between intermediate filament derived from epithelial cells and extracellular matrixes. Cell Struct. Funct. 2000; 25; 171-175.
47. Peng SY, Chen WJ, Lai PL et al. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int. J. Cancer 2004; 112; 44-50.
48. Tangkijvanich P, Anukulkarnkusol N, Suwangool P et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J. Clin. Gastroenterol. 2000; 31; 302-308.
49. Yabushita K, Yamamoto K, Ibuki N et al. Aberrant expression of cytokeratin 7 as a histological marker of progression in primary biliary cirrhosis. Liver 2001; 21; 50-55.
50. Nhieu JT, Renard CA, Wei Y et al. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am. J. Pathol. 1999; 155; 703-710.
51. Kondo Y, Kanai Y, Sakamoto M et al. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma. Jpn J. Cancer Res. 1999; 90; 1301-1309.
52. Laurent-Puig P, Legoix P, Bluteau O et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120; 1763-1773.
53. Uenishi T, Kubo S, Hirohashi K et al. Expression of bile duct-type cytokeratin in hepatocellular carcinoma in patients with hepatitis C virus and prior hepatitis B virus infection. Cancer Lett. 2002; 178; 107-112.
54. Sugimachi K, Taguchi K, Aishima S et al. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod. Pathol. 2001; 14; 900-905.
55. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatol. 2003; 37; 961-969.
56. Jarnagin WR, Weber S, Tickoo SK et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 2002; 94; 2040-2046.
57. Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum. Pathol. 1995; 26; 956-964.
58. Koh KC, Lee H, Choi MS et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am. J. Surg. 2005; 189; 120-125.
59. Cazals-Hatem D, Rebouissou S, Bioulac-Sage P et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J. Hepatol. 2004; 41; 292-298.